SK Biopharmaceuticals
SK Biopharmaceuticals, a leading player in the biopharmaceutical industry, is headquartered in South Korea (KR) and operates extensively across Asia, Europe, and North America. Founded in 2011, the company has rapidly established itself as a pioneer in developing innovative therapies for neurological disorders, particularly epilepsy. With a strong focus on research and development, SK Biopharmaceuticals has achieved significant milestones, including the successful launch of its flagship product, cenobamate, which offers unique mechanisms of action for seizure control. The company is recognised for its commitment to advancing healthcare solutions, positioning itself as a key contributor to the global biopharmaceutical landscape. Through its dedication to innovation and patient-centric approaches, SK Biopharmaceuticals continues to enhance its market presence and reputation.
DitchCarbon Score
How does SK Biopharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SK Biopharmaceuticals's score of 27 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SK Biopharmaceuticals's reported carbon emissions
In 2023, SK Biopharmaceuticals reported total carbon emissions of approximately 14,790,000 kg CO2e, comprising 433,000 kg CO2e from Scope 1, 1,046,000 kg CO2e from Scope 2, and 11,882,000 kg CO2e from Scope 3 emissions. This marked an increase in emissions compared to previous years, where in 2022, the total was about 13,610,000 kg CO2e, with 425,000 kg CO2e from Scope 1, 936,000 kg CO2e from Scope 2, and 6,547,000 kg CO2e from Scope 3. The company has disclosed emissions data for Scope 1 and Scope 2 for the years 2018 through 2023, showing a trend of fluctuating emissions. For instance, in 2021, total emissions were approximately 1,349,000 kg CO2e, while in 2020, they were about 1,211,000 kg CO2e. Despite these figures, SK Biopharmaceuticals has not set specific reduction targets or initiatives as part of their climate commitments, indicating a potential area for future development in their sustainability strategy. Overall, while SK Biopharmaceuticals has made strides in transparency regarding their emissions, the absence of defined reduction targets suggests that further action may be necessary to align with industry standards for climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 328,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 841,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SK Biopharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
